ALSN News (online only)
‘Smooth progress' reported in Neuralstem's human clinical trial of neural stem cells; FDA permission sought to proceed to cervical injections
Posted on Friday, June 17, 2011 - 11:21, By: Amy Madsen
Maryland biotherapeutics company Neuralstem has announced favorable results from the first part of a phase 1 trial to test the safety of its experimental spinal cord stem cell treatment in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
'ALS Starter Kit' will address equipment evaluations, health care teams, Medicare and other topics for those with a recent diagnosis and their families
Posted on Friday, May 20, 2011 - 14:41, By: Miriam Davidson
Every day in the United States, about 13 people receive a diagnosis of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease).
That’s 5,000 Americans a year who are new to this disease. MDA's ALS Division wants to reach out to these people and their families, encourage and support them, and most importantly, let them know they’re not alone.
News about 'NurOwn' stem cell therapy, nutrition and respiratory complications, vitamin E, the growth factor G-CSF, and low-dose naltrexone
Posted on Thursday, May 19, 2011 - 15:17, By: Amy Madsen
NurOwn stem cell therapy trial set to begin
Biotechnology company Brainstorm Cell Therapeutics announced May 17, 2011, that it has received approval from Israel's Ministry of Health to conduct a phase 1-2 clinical trial of stem cell therapy in adults with ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
A roundup of research about how the FUS gene and FUS protein may contribute to the development of amyotrophic lateral sclerosis
Posted on Thursday, May 12, 2011 - 16:37, By: Amy Madsen
The gene for FUS was associated in 2009 with some forms of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease).
Now, overlapping findings from four recent studies have revealed tantalizing clues about the molecular underpinnings of FUS-related forms of the disease.
News briefs about the Patients Like Me online study of lithium; the role of inflammation in ALS; and an upcoming webinar on ceftriaxone
Posted on Friday, April 29, 2011 - 14:44, By: Amy Madsen
Patients Like Me online lithium study utilized social media
An observational study of data self-reported on the online forum Patients Like Me by people with ALS who elected to take the drug lithium carbonate has shown two things:
Early results show ISIS-SOD1-Rx, an antisense drug directed against the SOD1 form of familial ALS, appears safe in the lowest-dose group
Posted on Wednesday, April 27, 2011 - 16:12, By: Margaret Wahl
Early results of a phase 1 clinical trial of ISIS-SOD1-Rx, an antisense oligonucleotide drug for SOD1-related amyotrophic lateral sclerosis (ALS), show the drug appears to be safe and well tolerated at the lowest dosage level, based on a group of six patients who received 12-hour infusions of it into their spinal fluid.
Connect with MDA
Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717
©2013, Muscular Dystrophy Association Inc.
All rights reserved.
All of contents copyright 2013 MDA All rights reserved.
